What Microdosing Your GLP-1 Actually Means (And Why I Get Asked About It Constantly)
I get some version of this question almost every week now. A patient will lean in at the trailer, or send me a message through the app, and ask if she should be "microdosing" her semaglutide instead of following the standard schedule. Sometimes it's a friend who saw a TikTok. Sometimes it's a patient who's already on a compounded product from somewhere else and wants to know if the dose she's on counts. Let's talk about what microdosing actually means, because the term gets used loosely and the answer matters for your safety and your wallet.
Microdosing a GLP-1 medication means taking a dose below the lowest FDA-approved starting dose. For semaglutide, that starting dose is 0.25 mg once weekly. Anything under that, sometimes as low as 0.05 mg, gets called a microdose.
Here's the part that should give you pause. There is no official medical definition of what counts as a microdose. It's not a recognized treatment category. No professional medical organization has endorsed it as a standard of care. The term migrated over from psychedelics research, where "microdose" meant an amount so small it wasn't considered pharmacologically active. Whether that idea translates cleanly to a peptide that stays in your system for weeks is a fair question nobody has answered yet.
The appeal makes sense on paper. People want three things: fewer side effects, lower cost, and a way to stay on the medication long term without the nausea and fatigue that can come with standard dosing.
The commercial GLP-1 pens from Novo Nordisk and Lilly are built for escalation, not for precision microdosing. They step you up from 0.25 mg toward a maintenance dose of 2.4 mg over months. If you want something below that starting point, in a consistent and verifiable amount, you generally need a compounding pharmacy to prepare it. That's a separate conversation with its own risks, since compounded GLP-1s are not FDA-approved products and quality varies by pharmacy.
Some people microdose to ease into treatment with less GI upset before ramping up. Others use it as a maintenance strategy once they've already hit their goal weight, spacing out or lowering their dose to hold steady rather than continuing to lose. Both are reasonable goals. What's missing is the data to tell us whether either approach actually works the way people hope.
This is where I have to be straight with you. As of right now, there is no meaningful long-term clinical data supporting microdosing for weight loss or for any other condition. A recent physician commentary in STAT News put it bluntly: there's no consensus definition of what a microdose even is, and no legitimate long-term evidence behind the trend. That doesn't mean it's impossible microdosing has a role. It means nobody has done the rigorous research yet to know who it helps, who it doesn't, and what the actual risk tradeoff looks like.
There is one decentralized trial currently underway looking at microdosed semaglutide and its effects on health, quality of life, and longevity measures. It's a start, but it hasn't reported results, and one trial won't settle the question.
If you're on a GLP-1 and you're struggling with side effects, that's a real conversation to have with your provider about titration speed, injection technique, and supportive strategies, not a reason to go find a fraction of a dose online without medical oversight. If you're maintaining your results and want to explore a lower dose, that's also worth discussing, but it needs to happen with someone who knows your full picture, not a protocol pulled from social media.
Microdosing isn't dangerous by definition. Doing it without a prescriber who actually knows your history, your labs, and your goals is where the real risk lives.
If you want to talk through where you are in your GLP-1 journey and whether a dose adjustment makes sense for you, message me through the Atlas MD app or reach out through www.presencemd.net. I'd rather have that conversation with you directly than have you guessing based on what's trending this week.
The basics: There isn't one landmark clinical trial behind the microdosing trend. This post draws on current medical reporting from Yale Medicine, NewYork-Presbyterian, Novant Health, and a physician opinion piece in STAT News, plus an ongoing decentralized trial sponsored by AgelessRx that has not yet reported results.
Who was in the study: Not applicable in the traditional sense. The AgelessRx trial is a decentralized study open to participants across all 50 states via telehealth, but results are not yet published.
What they did: Medical institutions and physicians have been evaluating the social media driven trend of taking GLP-1 doses below the FDA-approved starting amount and assessing what evidence, if any, supports the practice.
The results: No professional medical organization currently endorses microdosing as a standard of care. There is no agreed-upon definition of what constitutes a microdose, and no published long-term data on its safety or effectiveness for weight management.
Why it matters: Patients are increasingly seeking out microdosed or compounded GLP-1 products believing they offer a safer or more affordable path, often without physician oversight. Without data, providers can't tell patients what to actually expect.
The catch: Commercial GLP-1 pens aren't designed to deliver precise low doses, which pushes people toward compounded products that are not FDA-approved and vary in quality and safety by source.
How it works (probably): The theory is that a smaller dose still activates GLP-1 receptors enough to reduce appetite and slow gastric emptying, just with a gentler side effect profile. Whether that holds up at very low doses over long periods of use, especially for maintenance rather than weight loss, is exactly what remains unstudied.
Comments